Investigation Announcement: Kirby McInerney LLP is investigating potential claims against AVITA Medical, Inc. for possible violations of federal securities laws and unlawful business practices.
Financial Results Impact: On August 7, 2025, AVITA reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively affected first-half demand due to pricing issues with Medicare contractors.
Stock Price Decline: Following the announcement of the financial results, AVITA's stock price fell by approximately 21%, dropping from $5.38 to $4.25 per share.
Contact Information: Individuals who purchased AVITA securities or have relevant information can contact Thomas W. Elrod at Kirby McInerney LLP for further discussion regarding their rights or interests.
RCEL
$3.33+Infinity%1D
Analyst Views on RCEL
Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 8.38 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 8.38 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.400
Low
3.00
Averages
8.38
High
14.00
Current: 3.400
Low
3.00
Averages
8.38
High
14.00
BTIG
Sell -> Neutral
upgrade
2025-11-20
Reason
BTIG
Price Target
2025-11-20
upgrade
Sell -> Neutral
Reason
BTIG upgraded Avita Medical to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company's "wounds are starting to heal or at least cannot get materially much worse," the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.
Lake Street
Hold
downgrade
$4 -> $3
2025-11-07
Reason
Lake Street
Price Target
$4 -> $3
2025-11-07
downgrade
Hold
Reason
Lake Street lowered the firm's price target on Avita Medical to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.
TD Cowen
Buy
downgrade
$8
2025-10-20
Reason
TD Cowen
Price Target
$8
2025-10-20
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Avita Medical to $5.50 from $8 and keeps a Buy rating on the shares. The firm noted Avita Medical is moving through a leadership transition, but the interim CEO is an industry veteran who will focus on a Board-backed plan centered on execution. The roughly $17M preliminary 3Q revenue result underscores that reimbursement friction was real and lasted longer than hoped, but management believes the policy side is largely fixed exiting 3Q.
Lake Street
Frank Takkinen
Buy
to
Hold
downgrade
$8 -> $4
2025-10-17
Reason
Lake Street
Frank Takkinen
Price Target
$8 -> $4
2025-10-17
downgrade
Buy
to
Hold
Reason
Lake Street analyst Frank Takkinen downgraded Avita Medical to Hold from Buy with a price target of $4, down from $8. Q3 revenue did not rebound as anticipated and Jim Corbett resigned as CEO, with Chairman Cary Vance assuming the role as interim CEO, the analyst says. The firm is downgrading shares given the Q3 shortfall, a likely guidance reset, and OrbiMed debt requiring amendments, the analyst noted.
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
